Details for Patent: 8,114,874

Which drugs does patent 8,114,874 protect, and when does it expire?

Patent 8,114,874 protects ICLUSIG and is included in one NDA.

This patent has seventy patent family members in twenty countries.

Summary for Patent: 8,114,874

Title:	Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Abstract:	This invention relates to compounds of the general formula: ##STR00001## in which the variable groups are as defined herein, and to their preparation and use. In particular, the compounds include embodiments in which Ring T is an imidazo[1,2-b]pyridazine ring system, Rings A and B are each aryl and L.sup.1 is --C(O)NR.sup.1-- or --NR.sup.1C(O)--. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases.
Inventor(s):	Zou; Dong (Concord, MA), Huang; Wei-Sheng (Acton, MA), Thomas; R. Mathew (Waltham, MA), Romero; Jan Antionette C. (Cambridge, MA), Qi; Jiwei (West Roxbury, MA), Wang; Yihan (Newton, MA), Zhu; Xiaotian (Newton, MA), Shakespeare; William C. (Southborough, MA), Sundaramoorthi; Rajeswari (Chennai, IN), Metcalf, III; Chester A. (Needham, MA), Dalgarno; David C. (Brookline, MA), Sawyer; Tomi K. (Southborough, MA)
Assignee:	ARIAD Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	11/644,849
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,114,874
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 8,114,874

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-004	Dec 18, 2020		RX	Yes	No			Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-001	Dec 14, 2012		RX	Yes	No			Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-003	Apr 23, 2015		RX	Yes	No			Y	Y
Takeda Pharms Usa	ICLUSIG	ponatinib hydrochloride	TABLET;ORAL	203469-002	Dec 14, 2012		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,114,874

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006331673
Australia	2007249924
Australia	2007249926
Brazil	PI0621098